PI-PLCβ-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes [5]

Leukemia

Volumn 22, Issue 1, 2008, Pages 198-200

  Follo, M Y ^a   Finelli, C ^a   Bosi, C ^a,b   Martinelli, G ^a   Mongiorgi, S ^a   Baccarani, M ^a   Manzoli, L ^a   Blalock, W L ^a   Martelli, A M ^a,c   Cocco, L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Ospedale Civile di Piacenza   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; DEFEROXAMINE; PHOSPHATIDYLINOSITIDE; PHOSPHOLIPASE C BETA1; PROTEIN KINASE B; ENZYME INHIBITOR; PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE C BETA; PLCB1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; BLOOD TRANSFUSION; CASE REPORT; CORRELATION ANALYSIS; DEMETHYLATION; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; LETTER; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA SPLICING; SIGNAL TRANSDUCTION; METABOLISM; MIDDLE AGED;

AZACITIDINE; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHOSPHATIDYLINOSITOLS; PHOSPHOLIPASE C BETA; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 38349023105     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404855     Document Type: Letter

References (8)

1. Cocco L, Martelli AM, Fiume R, Faenza I, Billi AM, Manzoli FA. Signal transduction within the nucleus: Revisiting phosphoinositide inositide-specific phospholipase Cbeta1. Adv Enzyme Regul 2006; 46: 2-11.
2. Lo Vasco VR, Calabrese G, Manzoli L, Palka G, Spadano A, Morizio E et al. Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 2004; 18: 1122-1126.
3. Folio MY, Bosi C, Finelli, C, Fiume R, Faenza I, Ramazzotti G et al Real-time PCR as a tool for quantitative analysis of PI-PLCβ1 gene expression in myelodysplastic syndrome. Int J Mol Med 2006; 18 267-271.
4. Folio MY, Mongiorgi S, Bosi C, Cappellini A, Finelli C, Chiarini F et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res 2007; 67: 4287-4294.
5. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL et al Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005; 11: 3604-3608.
6. Silverman LR, Demakos EP, Peterson BL, Komblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440.
7. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957-2964.
8. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.